Generate Biomedicines (Ticker: GENB US) is an American clinical-stage generative biology company specializing in artificial intelligence for biotechnology and drug design. Generate Biomedicines plans to list on the NASDAQ on February 27, 2026, planning to offer 25.0 million shares at a price range of $15.00 to $17.00, raising an estimated $400 million. The company is projected to have a market capitalization of approximately $2 billion

The company operates a proprietary platform integrating computational innovation with scalable biohardware to engineer novel therapeutics. According to sources, the company has progressed three computationally engineered proteins into human testing, including GB-0895, an investigational monoclonal antibody currently in Phase 3 clinical trials for severe asthma. Additional candidates targeting oncology are reportedly expected to advance into Phase 1 trials in 2026. The company is domiciled in the United States, originally founded in 2018. The IPO will reportedly be managed by joint bookrunners including Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor.